MIA researchers share learnings on global stage at ASCO23

Melanoma Institute Australia at ASCO 2023 

Speakers

1. Ines Pires Da Silva – Tough Nuts to Crack in Cutaneous Oncology – Discussant in Melanoma/ Skin Cancers Oral Abstract Session

2. Helen Rizos – Beyond Tissue Biopsies: Liquid Biomarkers in Melanoma – in Knowing the Unknown: The Future of Prognostic Tools in Melanoma Education Session

3. Irene Reijers, Alexander Menzies, Judith Versluis, Robyn Saw, Winan van Houdt, Ellen Kapiteijn, Astrid Van Der Veldt, Karijn Suijkerbuijk, Hanna Eriksson, Geke Hospers, Willem Klop, Marta Lopez-Yurda, Lindsay Grijpink-Ongering, Maria Gonzalez, Andrew Spillane, Richard Scolyer, Bart van de Wiel, Alexander Van Akkooi, Georgina Long, Christian Blank – The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo – in Clinical Science Symposium

4. Merve Hasanov, Denai Milton, Serigne Lo, Jeffrey Gershenwald, Julie Simon, Georgina Long, Richard Scolyer, Michael Davies – External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma – in Clinical Science Symposium

Oral Abstract Presentations

1. Georgina Long, John M. Kirkwood, Christoph Hoeller, Jean-Jacques Grob, Jeffrey Weber, Janis Taube, Peter Mohr, Alexander Van Akkooi, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Daniel Tenney, Sonia Dolfi, Hao Tang, Corey Ritchings, Maurice Lobo, Federico Campigotto, Wenjia Wang, Brian Gastman, Michele Del Vecchio – Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K) – oral abstract presentation

2. Jason Luke, Paolo Ascierto, Muhammad Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo Carlino, Larry Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander Eggermont, Georgina Long – Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study – oral abstract presentation

3. Hussein Tawbi, F. Hodi, Evan Lipson, Dirk Schadendorf, Paolo Ascierto, Luis Matamala, Erika Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Barbara Ratto, Saima Rodriguez, Yuanfang Xu, Sonia Dolfi, Georgina Long – Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047 – oral abstract presentation

4. Adnan Khattak, Jeffrey Weber, Tarek Meniawy, Matthew Taylor, George Ansstas, Kevin Kim, Meredith McKean, Georgina Long, Ryan Sullivan, Mark Faries, Thuy Tran, Charles Cowey, Theresa Medina, Jennifer Segar, Victoria Atkinson, Geoffrey Gibney, Jason Luke, Elizabeth Buchbinder, Robert Meehan, Matteo Carlino – Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial – oral abstract presentation

Poster Discussion

1. Piyush Grover, Isabel Li, Anke Kuijpers, Firas Kreidieh, Andrew Williamson, Teresa Amaral, Florentia Dimitriou, Joanna Placzke, Kelly Olino, Maria Vitale, Philippe Saiag, Ralf Gutzmer, Clara Allayous, Roger Olofsson Bagge, Nethanel Asher, Tarek Meniawy, Aleigha Lawless, Lydia Warburton, Alexander Menzies, Georgina Long – Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma – poster discussion

2. Matteo Carlino, Adnan Khattak, Jeffrey Weber, Tarek Meniawy, Ryan Sullivan, Matthew Taylor, Kevin Kim, Meredith McKean, Mark Faries, Charles Cowey, Geoffrey Gibney, Jason Luke, Sajeve Thomas, Vasudha Sehgal, Igor Feldman, Praveen Aanur, Michelle Brown, Robert Meehan, Celine Robert-Tissot, Georgina Long – Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab. – poster discussion

3. Minke Lucas, Petros Dimitriadis, Irene Reijers, Alexander Menzies, Elisa Rozeman, Judith Versluis, Alexander Huang, Sten Cornelissen, Annegien Broeks, Richard Scolyer, Tara Mitchell, Georgina Long, Christian Blank – Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis – poster discussion

4. Antony Mersiades, Adrienne Kirby, Martin Stockler, Annette Tognela, Ian Olver, Rachael Morton, Paul Haber, Anna Walsh, Yvonne Lee, Ehtesham Abdi, Stephen Della-Fiorentina, Morteza Aghmesheh, Peter Fox, Karen Briscoe, Jasotha Sanmugarajah, Gavin Marx, Ganessan Kichenadasse, Helen Wheeler, John Simes, Peter Grimison – Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial – poster discussion

Poster Abstract

1. Georgina Long, Alexander Eggermont, Jeffrey Gershenwald, Dirk Schadendorf, Paolo Ascierto, Reinhard Dummer, Axel Hauschild, Matteo Carlino, Antoni Ribas, Caroline Robert, Richard Scolyer, Vernon Sondak, Jonathan Cohen, Jinchun Zhang, Dmitri Grebennik, Clemens Krepler, Jason Luke – KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma – poster presentation

2. Maria Gonzalez, Alexander Van Akkooi, Andrew Spillane, Sydney Ch’ng, Kerwin Shannon, Jonathan Stretch, Michael Rtshiladze, Thomas Pennington, Robyn Saw, Alexander Menzies, Robert Rawson, Linda Martin, Pascale Guitera, Mary Jane Gregorio, Kevin London, Rony Kapoor, Edward Hsiao, Serigne Lo, Richard Scolyer, Georgina Long – . A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II– poster presentation

3. Rachel Woodford, Janet McKeown, Lotte Hoeijmakers, Joanna Mangana, Celeste Lebbe, Farzana Zaman, Francisco Aya, John Marsiglio, Rachel Goodman, Victoria Rayson, Joanna Placzke, Jolien Kessels, Egle Ramelyte, Waqas Haque, Isabella Wilson, Claudia Trojaniello, Rachel Roberts-Thomson, Caroline Robert, Georgina Long, Alexander Menzies – Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy – poster presentation

4. Alexander Van Akkooi, Axel Hauschild, Georgina Long, Mario Mandalà, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul Lorigan, Alexander Eggermont – Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design – poster presentation

5. Piyush Grover, Isabel Li, Alexander Menzies, Georgina Long – Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID) – poster presentation

6. Rasmus Mikiver, Roger Olofsson Bagge, Michael Marchetti, Alexander Van Akkooi, Daniel Coit, Christian Ingvar, Karolin Isaksson, Richard Scolyer, John Thompson, Alexander Varey, Johan Lyth, Edmund Bartlett – Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma – poster presentation

7. Irene Reijers, Itske Fraterman, Petros Dimitriadis, Annegien Broeks, Maria Gonzalez, Alexander Menzies, Ellen Kapiteijn, Astrid Van Der Veldt, Karijn Suijkerbuijk, Geke Hospers, Georgina Long, Christian Blank, Lonneke van de Poll-Franse – The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma – poster presentation

8. Rachel Goodman, Aleigha Lawless, Rachel Woodford, Asha Tipirneni, James Patrinely, Hui-Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Janice Mehnert, Georgina Long, Ryan Sullivan, Matteo Carlino, Alexander Menzies, Douglas Johnson – Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma – poster presentation

9. Lisa Zimmer, Florentia Dimitriou, Piyush Grover, Jessica Hassel, Michael Erdmann, Andrea Forschner, Douglas Johnson, Elisabeth Livingstone, Alexander Roesch, Selma Ugurel, Carsten Schulz, Carola Berking, Alexander Menzies, Georgina Long, Reinhard Dummer, Dirk Schadendorf, Lea Jessica Albrecht – Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma – poster presentation

10. Lisanne Zijlker, Winan van Houdt, Emma Stahlie, Viola Franke, Maartje Rohaan, Antonios Delatzakis, Charlotte Zuur, Willem Klop, Bart van de Wiel, Anke Kuijpers, Elianne de Boer, Johannes van Thienen, John Haanen, Alexander Van Akkooi – Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial – poster presentation

11. Dirk Schadendorf, Hussein Tawbi, Evan Lipson, F. Hodi, Paolo Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana Horton, Jenny Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Leon Sakkal, Georgina Long – Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD) – poster presentation

12. Ana Baramidze, Miranda Gogishvili, Tamta Makharadze, Mariam Zhvania, Khatuna Vacharadze, John Crown, Tamar Melkadze, Omid Hamid, Georgina Long, Caroline Robert, Mario Sznol, Hector Martinez-Said, Jayakumar Mani, Usman Chaudhry, Mark Salvati, Israel Lowy, Matthew Fury, Giuseppe Gullo – A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma – poster presentation